S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
NASDAQ:ACOR

Acorda Therapeutics News Headlines

$1.80
-0.08 (-4.26%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.78
$1.93
50-Day Range
$1.80
$3.64
52-Week Range
$1.78
$8.66
Volume
135,087 shs
Average Volume
101,182 shs
Market Capitalization
$20.16 million
P/E Ratio
1.15
Dividend Yield
N/A
Beta
0.49
Get Acorda Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Acorda Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACOR
News Sentiment

-0.10

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACOR Articles
This Week

1

1

ACOR Articles
Average Week



Acorda Therapeutics (NASDAQ:ACOR) News Headlines Today

SourceHeadline
nasdaq.com logoAcorda Therapeutics Inc Shares Close in on 52-Week Low - Market Mover
nasdaq.com - January 16 at 3:58 AM
finance.yahoo.com logoAcorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
finance.yahoo.com - January 4 at 7:31 AM
nasdaq.com logoAcorda Therapeutics Inc Shares Approach 52-Week Low - Market Mover
nasdaq.com - December 25 at 8:57 AM
benzinga.com logoWorldwide Multiple Sclerosis Drugs Industry to 2027 - Featuring Abbvie, Acorda Therapeutics and Biogen Among Others - ResearchAndMarkets.com
benzinga.com - December 10 at 6:46 PM
nasdaq.com logoAcorda Therapeutics Inc Shares Fall 3.9% Below Previous 52-Week Low - Market Mover
nasdaq.com - November 29 at 11:16 PM
nasdaq.com logoAcorda Therapeutics Inc Shares Fall 5.0% Below Previous 52-Week Low - Market Mover
nasdaq.com - November 27 at 12:39 AM
ca.finance.yahoo.com logoGlobal Ataxia Treatment Market to Surpass US$ 47,360.7 Million by 2028, Says Coherent Market Insights (CMI)
ca.finance.yahoo.com - November 15 at 1:02 PM
nz.finance.yahoo.com logoAcorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany
nz.finance.yahoo.com - November 9 at 7:34 PM
benzinga.com logoEarnings Outlook For Acorda Therapeutics
benzinga.com - November 8 at 1:17 PM
finance.yahoo.com logoAcorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021
finance.yahoo.com - November 2 at 11:04 AM
marketwatch.com logoPost herpetic Neuralgia Treatment Market Growth Estimation, Geography Trends, Business Statistics, Developing Trends and Forecast 2026
marketwatch.com - October 28 at 11:02 PM
marketwatch.com logoDalfampridine Market Size, Segmented by Product Type, Applications, Distribution Channel, Growth, Trends, and Forecast 2027
marketwatch.com - October 26 at 2:23 PM
seekingalpha.com logoAcorda Therapeutics: Managing The Transition
seekingalpha.com - October 4 at 4:59 PM
marketwatch.com logoPost Herpetic Neuralgia Therapies Market Research Report Includes Size, Capacity, Production, Revenue, Gross Margin, Forecast to 2027
marketwatch.com - September 14 at 3:18 AM
nasdaq.com logoAcorda Therapeutics To Reduce Headcount; Names Lauren Sabella COO - Quick Facts
nasdaq.com - September 9 at 12:18 PM
finance.yahoo.com logoAcorda Therapeutics Announces Corporate Restructuring, Management Changes
finance.yahoo.com - September 9 at 12:18 PM
benzinga.com logoReturn on Capital Employed Insights for Acorda Therapeutics
benzinga.com - August 27 at 11:10 PM
finance.yahoo.com logoAcorda Therapeutics Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 5 at 7:31 PM
markets.businessinsider.com logoHere's what to expect from Acorda Therapeutics's earnings report
markets.businessinsider.com - August 3 at 7:39 PM
finance.yahoo.com logoAcorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
finance.yahoo.com - July 30 at 5:46 PM
finance.yahoo.com logoWill Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - July 27 at 7:43 PM
seekingalpha.com logoAcorda Therapeutics Continues To Maneuver For A Turnaround
seekingalpha.com - July 24 at 1:57 AM
marketwatch.com logoAcorda Therapeutics Shares Up Friday After Deal to Commercialize Inbrija in Spain
marketwatch.com - July 23 at 5:49 PM
baystreet.ca logoAcorda Flies on new Supply Deal
baystreet.ca - July 23 at 12:44 PM
marketwatch.com logoAcorda Therapeutics in Deal to Commercialize Inbrija in Spain
marketwatch.com - July 22 at 8:22 PM
marketwatch.com logoAcorda Therapeutics Shares up After Deal to Commercialize Inbrija in Spain
marketwatch.com - July 22 at 8:22 PM
finance.yahoo.com logoAcorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
finance.yahoo.com - July 22 at 8:22 PM
nasdaq.com logoAcorda Therapeutics, Inc. Common Stock (ACOR)
nasdaq.com - July 13 at 12:56 AM
benzinga.com logoInsights on the Spinal Cord Trauma Treatment Global Market to 2027 - Featuring Acorda Therapeutics, BioTime and Pfizer Among Others
benzinga.com - June 21 at 1:23 PM
finance.yahoo.com logoHedge Funds Are Buying Acorda Therapeutics Inc (ACOR) Again
finance.yahoo.com - June 19 at 12:50 AM
finance.yahoo.com logoAcorda Therapeutics Announces Repayment of Convertible Senior Notes
finance.yahoo.com - June 16 at 9:29 AM
seekingalpha.com logoAcorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 7 at 11:27 AM
msn.com logoBRIEF-Acorda Therapeutics Reports First Quarter 2021 Financial Results
msn.com - May 6 at 5:34 PM
finance.yahoo.com logoAcorda Therapeutics Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 6 at 5:34 PM
seekingalpha.com logoAcorda Therapeutics: Buying Before The Coast Is Clear
seekingalpha.com - April 29 at 9:19 PM
finance.yahoo.com logoAcorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021
finance.yahoo.com - April 29 at 6:48 PM
finance.yahoo.com logoAll You Need to Know About Acorda (ACOR) Rating Upgrade to Strong Buy
finance.yahoo.com - April 27 at 5:31 PM
benzinga.com logoSpinal Cord Injury Clinical Trials Review: A Multitude of Emerging Drugs for Better Treatment
benzinga.com - April 21 at 10:41 PM
finance.yahoo.com logoJ&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales
finance.yahoo.com - April 20 at 3:23 PM
marketwatch.com logoUsing the Action in Acorda Therapeutics $ACOR to our Advantage
marketwatch.com - March 16 at 9:44 AM
finance.yahoo.com logoVertex (VRTX) Type I Diabetes Candidate Clinical Study Begins
finance.yahoo.com - March 11 at 12:17 PM
finance.yahoo.com logoHas Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?
finance.yahoo.com - March 10 at 1:34 PM
finance.yahoo.com logoThe Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Just Boosted Their Forecasts By A Dazzling Amount
finance.yahoo.com - March 9 at 8:19 AM
finance.yahoo.com logoAcorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
finance.yahoo.com - March 8 at 7:44 PM
finance.yahoo.com logoQIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing
finance.yahoo.com - March 5 at 6:04 PM
seekingalpha.com logoAcorda Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 5 at 2:16 PM
msn.com logo11 Stocks Moving In Thursday's After-Hours Session
msn.com - March 4 at 8:51 PM
finance.yahoo.com logoAcorda: Q4 Earnings Snapshot
finance.yahoo.com - March 4 at 8:51 PM
finance.yahoo.com logoAcorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 4 at 8:51 PM
markets.businessinsider.com logoAcorda Therapeutics is about to announce earnings — here's what Wall Street expects
markets.businessinsider.com - March 2 at 1:31 PM
Get Acorda Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.